Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inhaled Insulin Returns To The U.S. Market With Afrezza Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi announced the launch of the inhaled insulin in the U.S. Feb. 3, priced at a wholesale acquisition cost that is higher than rival injectable mealtime insulins.

You may also be interested in...



Sanofi Board Forces CEO Chris Viehbacher to Resign Amid Lantus Woes

Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.

Afrezza Launch Waits On Marketing Partner; MannKind Ramps Up Production

Production of insulin powder inhaler cartridges at Connecticut facility will triple to 400 million a year by launch, which firm expects in 2015.

Rocket Fires Up CV Gene Therapy Pipeline With Renovacor Merger

Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel